An open label, expanded access protocol intended to provide treatment with MP-104 (deflazacort) to U.S. children, adolescents, and/or adults with Duchenne muscular dystrophy

Project: Research project

Project Details

StatusActive
Effective start/end date4/26/168/31/50

Funding

  • Marathon Pharmaceuticals, LLC
  • Marathon Pharmaceuticals, LLC